Skip to main content

ALK Gene Rearrangement clinical trials at UC Health
2 in progress, 1 open to eligible people

  • A Study of Chemotherapy with Experimental Crizotinib vs. Placebo For Non-Small Cell Lung Cancer After Surgery

    β€œCan targeted chemotherapy with Crizotinib, stop the growth of tumor cells by blocking the a protein from working?”

    open to eligible people ages 18 years and up

    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

    at UC Davis UCSD

  • Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

    Sorry, not yet accepting patients

    This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    at UCSF

Last updated: